Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro

M.D. Norris, J. Smith, K. Tanabe, P. Tobin, C. Flemming, G.L. Scheffer, P Wielinga, S.L. Cohn, W.B. London, G.M. Marshall, JD Allen, M. Haber

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)547-553
JournalMolecular Cancer Therapeutics
Issue number4
Publication statusPublished - 2005

Cite this